United Therapeutics (UTHR) Reports INCREASE Study of Tyvaso Meets Primary and All Secondary Endpoints
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
- Oil prices settle at pre-Iran war levels as crude output grows
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
United Therapeutics (UTHR) Misses Q4 EPS by 69c, Revenues Miss
February 26, 2020 6:07 AM ESTUnited Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $1.96, $0.69 worse than the analyst estimate of $2.65. Revenue for the quarter came in at $311.1 million versus the consensus estimate of $357.77 million.
"Following the positive results of the INCREASE study of Tyvaso® (treprostinil) Inhalation Solution in pulmonary hypertension associated with interstitial lung disease (ILD), we're looking forward to submitting a... More
United Therapeutics (UTHR), DEKA Report Additional FDA Clearance Related to Unity Subcutaneous Delivery System for Remodulin
February 24, 2020 6:18 AM ESTUnited Therapeutics Corporation (NASDAQ: UTHR) and DEKA Research & Development Corp. today announced receipt of an additional 510(k) clearance by the U.S. Food and Drug Administration (FDA) related to the Unity Subcutaneous Delivery System for Remodulin® (treprostinil) Injection, also referred to as the Remunity pump, enabling United Therapeutics to launch the system using drug reservoirs that have been prefilled by specialty pharmacies.
The Remunity system, which was jointly developed by United Therapeutics and DEKA, is indicated for continuous subcutaneous delivery of Remodulin to treat pulmonary arterial... More
